RT Journal Article
SR Electronic
T1 Healthcare personnel knowledge, motivations, concerns and intentions regarding COVID-19 vaccines: a cross-sectional survey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.19.21251993
DO 10.1101/2021.02.19.21251993
A1 Jain, Vivek
A1 Doernberg, Sarah B.
A1 Holubar, Marisa
A1 Huang, Beatrice
A1 Marquez, Carina
A1 Brown, Lillian
A1 Rubio, Luis
A1 Sample, Hannah A.
A1 Bollyky, Jenna
A1 Padda, Guntas
A1 Valdivieso, Daisy
A1 Kempema, Amanda
A1 Leung, Christopher
A1 Sklar, Matthew
A1 Julien, Aida
A1 Paoletti, Marcus
A1 Jaladanki, Sravya
A1 Wan, Emerald
A1 Ghahremani, Jacob
A1 Chao, Jessica
A1 Weng, Yingjie
A1 Lu, Di
A1 Glidden, David
A1 Grumbach, Kevin
A1 Maldonado, Yvonne
A1 Rutherford, George
YR 2021
UL http://medrxiv.org/content/early/2021/02/23/2021.02.19.21251993.abstract
AB Background Healthcare personnel (HCP) are prioritized for earliest SARS-CoV-2 vaccine administration, yet relatively few data exist on HCP’s knowledge, motivations, concerns, and intentions regarding COVID-19 vaccines.Methods We conducted a cross-sectional survey Nov.16-Dec.8, 2020 among HCP enrolled in a cohort study at three Northern California medical centers serving diverse roles including COVID-19 patient care. Eligible HCP were adult (age≥18) on-site employees of the University of California, San Francisco, San Francisco General Hospital, and Stanford Healthcare. A one-time electronically-administered survey was sent to cohort HCP on November 16, 2020 and responses analyzed.Results Overall, among 2,448 HCP invited, 2,135 completed the COVID-19 vaccine survey (87.2% response rate). HCPs had mean age 41 years, were 73% female, and had diverse jobs including COVID-19 patient contact. Enthusiasm for vaccination was overall strong, and more HCP (1,453, 69%) said they would definitely/likely receive vaccine if formally FDA-approved versus if approved via emergency use authorization only (785, 35%). While 541 (25%) respondents wanted to be among the earliest to receive vaccine, more desired vaccination after the first round (777, 36%) or >2 months after vaccinations began (389, 18%). Top factors increasing motivation for vaccination included perceiving risk from COVID-19 to self (1,382, 65%) or to family/friends (1355, 63%). Top concerns were vaccine side effects, cited by 596 (28%), and concerns about political involvement in FDA’s approval process (249, 12%).Conclusions HCP were enthusiastic about COVID-19 vaccination for individual protection and protecting others, but harbored concerns about vaccine side effects. Our data may inform emerging vaccine education campaigns.Key Points Among 2,135 healthcare personnel surveyed, we found enthusiasm for COVID-19 vaccination both for individual benefit and protecting others. However, healthcare personnel rated their knowledge of COVID-19 vaccines as only moderate and harbored concerns about vaccine side effects. Education raising awareness of vaccine efficacy and side effects may help maximize vaccine uptake.Competing Interest StatementVivek Jain: Funding from President's Emergency Plan for AIDS Relief and CDC (UO1GH002119), unrelated to this study. Sarah Doernberg: Consultant, Genentech and Basilea Pharmaceutica, unrelated to this study. Funding from the NIH (UM1AI104681) for work unrelated to this study. All authors: Research grant funding from the Chan Zuckerberg Initiative for this work.Funding StatementStudy funded by a research grant from the Chan Zuckerberg Initiative. Authors have not received payment or services from any third party for any aspect of the work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The CHART Study and the COVID-19 vaccine survey were approved by the UCSF Committee on Human Subjects Research and the Stanford University School of Medicine Panel on Human Subjects in Medical Research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesContact corresponding author Vivek Jain at vivek.jain@ucsf.edu.